Skip to main content
Alzheimer's & Dementia logoLink to Alzheimer's & Dementia
. 2025 Dec 23;21(Suppl 8):e110062. doi: 10.1002/alz70862_110062

Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab

Nelly Joseph‐Mathurin 1,, Charles D Chen 2, Diana A Hobbs 1, Meng Jiang 1, Shaney Flores 1, Jalen Scott 1, Sanjana Anand 1,3, Erin E Franklin 1, Ruijin Lu 1, Brian A Gordon 1, Clifford R Jack Jr 4, Carlos Cruchaga 1, Jason J Hassenstab 1, Laura Ibanez 1, Yan Li 1, Guoqiao Wang 1, Alan E Renton 5, Chengjie Xiong 1, Alireza Atri 6, B Joy Snider 1, Jorge J Llibre‐Guerra 1, David B Clifford 1, Eric McDade 1, Randall J Bateman 1, Qing Wang 1, Richard J Perrin 1, Tammie LS Benzinger 7
PMCID: PMC12725136

Abstract

Background

Amyloid related imaging abnormality edema (ARIA‐E) occurs in about 19% of individuals with autosomal dominant Alzheimer disease (ADAD) treated with an anti‐amyloid‐b monoclonal antibody (Salloway et al., 2021). In a previously reported case, ARIA‐E appeared to colocalize with decreases in PiB‐PET uptake (Joseph‐Mathurin, Llibre‐Guerra, et al, 2022), suggesting an association between amyloid‐b (Aβ) removal and ARIA‐E. Here, we compare longitudinal neuroimaging and corresponding neuropathology in an ADAD individual treated with gantenerumab, who experienced multiple ARIA‐E episodes as sulcal effusions that resolved by the end of the four‐year trial.

Methods

PiB‐PET and MRI were collected pre‐ and post‐randomization (2 and 4 years). The participant consented to brain donation, which was received a year after trial completion. Four tissue samples were taken from the location of the ARIA‐E in the parieto‐occipital left hemibrain as identified by MRI (one block contained the sulcus affected by ARIA‐E; the rest of the coronal section was captured in the remaining three blocks). Area fractions (AFs) of Aβ (10D5 immunohistochemistry (IHC)), tauopathy (PHF1), microglia (Iba1), and astrocytes (GFAP) in one sulcal region of interest (ROI) from each block and PiB‐PET SUVRs of corresponding ROIs were extracted (n = 4, Figure 1). Additionally, we included PiB‐PET SUVRs corresponding to ARIA‐E findings observed in the right hemisphere at baseline, two‐year, and four‐year visits (n = 6).

Results

Overall PiB‐PET uptake increased during the first two years (before ARIA‐E) and decreased during the last two years (including ARIA‐E episodes) (0.03±0.05 vs. ‐0.04±0.04 SUVR/year, p‐value=0.01, Figure 2). The decrease seemed more pronounced in ARIA‐E ROIs versus normal‐appearing sulcus ROIs (‐0.05±0.04 vs. ‐0.02±0.03 SUVR/year). Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p‐value=0.07). The ARIA‐E ROI had an Aβ AF of 0.009 while normal‐appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3). AFs for tauopathy, microglia, and astrocytes were within the range of those of normal‐appearing sulcus ROIs, suggesting an Aβ‐specific effect, although unexamined markers may play a role.

Conclusions

Our preliminary findings indicated that ARIA‐E is associated with longitudinal PiB‐PET decrease and Aβ AF, supporting the link between ARIA‐E, changes in PiB‐PET, and local Aβ removal observed at autopsy.

Funding: K01AG080123; U01AG042791; R01AG046179; R01AG053267


graphic file with name ALZ-21-e110062-g002.jpg

graphic file with name ALZ-21-e110062-g001.jpg

graphic file with name ALZ-21-e110062-g003.jpg


Articles from Alzheimer's & Dementia are provided here courtesy of Wiley

RESOURCES